CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content

Gabapentin for HIV-associated Neuropathic Pain: A Review of the Clinical Effectiveness

Last updated: January 22, 2016
Project Number: RC0750-000
Product Line: Rapid Response
Research Type: Drug
Report Type: Summary with Critical Appraisal
Result type: Report


  1. What is the clinical effectiveness of gabapentin for the treatment of HIV-associated neuropathic pain?

Key Message

There is limited evidence for the use of gabapentin for the treatment of HIV-associated neuropathy. One relevant RCT, included in a systematic review, and one non-randomized study were identified. The studies suggest that gabapentin may improve pain and related sleep disturbances caused by HIV-associated sensory neuropathy; however, due to the limitations of the evidence, the effectiveness of gabapentin for patients with HIV-associated neuropathy is inconclusive.